Catherine Cannon

TL;DR: Results indicate that antibodies can cross the blood–brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.

TL;DR: In vitro adhesion assay on tissue sections found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels, and therapies designed to interfere with α4βl integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.

TL;DR: Results indicate that antibody Fc-mediated plaque clearance is a highly efficient and effective process for protection against neuropathology in an animal model of Alzheimer's disease.

TL;DR: Clinical improvement was accompanied by a marked decrease in abnormal pathological findings, including demyelination, therefore anti-α4 is an effective treatment of EAE and may be similarly useful in the treatment of autoimmune diseases such as multiple sclerosis.

TL;DR: A monoclonal antibody is described, 15/7, that recognizes a high affinity or ligand-occupied conformation of β1 integrin, which provides insight into how cells maintain different constitutive levels of α4β1Integrin activity, and how the activity of β 1 integrin can be modulated by activators of cell adhesion.